Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15898744 | 1.00 | ACHE (0.34) | ACHETAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL15763414 | 0.92 | ACHE (0.34) | ACHETAS1R3TAS1R1 | |
| SCHEMBL15898784 | 0.92 | ACHE (0.34) | ACHEALDH1A1 | |
| SCHEMBL13030113 | 0.90 | ACHE (0.43) | ACHETAS1R3TAS1R1 | |
| SCHEMBL31514886 | 0.90 | ACHE (0.43) | ACHETAS1R3TAS1R1 | |
| SCHEMBL15763460 | 0.88 | ACHE (0.32) | ACHE | |
| SCHEMBL15763412 | 0.84 | ACHE (0.34) | ACHE | |
| SCHEMBL10238971 | 0.83 | ACHE (0.39) | ACHETAS1R3TAS1R1 | |
| SCHEMBL21136248 | 0.83 | ACHE (0.36) | ACHE | |
| SCHEMBL15898757 | 0.83 | ACHE (0.39) | ACHETAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394331-B2 | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections | GILEAD PHARMASSET LLC (US) | 2016-07-19 | — | — | US | disclosed |
| US-8841275-B2 | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections | GILEAD PHARMASSET LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120142626-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142626-A1 | COMPOUNDS | HAVCR2, EIF2AK2, NTPCR | ACHE 3340/4885TAS1R3 3457/4885TAS1R1 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.